AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01290042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 181
Description: Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
Study NCT01290042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for AMG 181
Description: Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
Study NCT04212715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic SABR with intra-prostatic SABR
Description: SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® Respimat®, low inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, low inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® Respimat®, medium inspiratory flow rate
Study NCT00432913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic Acid (EPA)
Description: Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, medium inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® Respimat®, high inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, high inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® HFA-MDI, low inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® HFA-MDI, low inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® HFA-MDI, medium inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® HFA-MDI, medium inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® HFA-MDI, high inspiratory flow rate
Study NCT02176200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® HFA-MDI, high inspiratory flow rate
Study NCT04178928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
Study NCT03118336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10Mg Tab
Description: 1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
Study NCT03118336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 10Mg Tab
Description: 1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
Study NCT01591408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG biofeedback
Description: EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
Study NCT01591408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EEG biofeedback
Description: EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
Study NCT00886769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
Study NCT00886769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
Study NCT05231759 — intervention group
Intervention type: DEVICE
Intervention: L'DISQ
Study NCT00405730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 1mg/ml eye drops, suspension
Description: One drop in the study eye 3 times daily for 23 days
Study NCT00405730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Trometamol 5 mg/ml eye drops, solution
Description: One drop in the study eye 3 times daily for 23 days
Study NCT00405730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac vehicle eye drops
Description: One drop in the study eye 3 times daily for 23 days
Study NCT03456258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete blood count
Description: To measure hemoglobin difference and serum ferritin levels .
Study NCT02559973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
Study NCT02559973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBP-6000
Description: RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
Study NCT02559973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBOXONE Sublingual Film
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
Study NCT02559973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBOXONE Sublingual Film
Description: Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
Study NCT02916069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nearinfrared Spectroscopy (NIRS)
Description: Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
Study NCT02916069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Doppler (TCD)
Description: Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
Study NCT02916069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index (BIS)
Description: Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
Study NCT04650230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices
Study NCT00709150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative depression care management
Description: Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
Study NCT00709150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
Study NCT02473471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: At baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: At baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical chemistry
Description: Full blood count at baseline, month 3 and month 6.
Study NCT00977860 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: 36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
Study NCT00149162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: proleukin
Description: One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months
Study NCT02895230 — intervention group
Intervention type: OTHER
Intervention: Standard care
Description: An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
Study NCT01698372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena device (Group A)
Description: This portable device is applied to initiate negative pressure therapy to a wound site.
Study NCT04003012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT04003012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1%
Study NCT02129998 — intervention group
Intervention type: OTHER
Intervention: IVF/ICSI treatment
Study NCT01906398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ketogenic diet
Description: KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
Study NCT04353271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
Study NCT04353271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
Study NCT00224445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg capsule administered orally QD
Study NCT03159273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice Group
Description: Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
Study NCT04048382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Clinical chemistry
Description: Full blood count at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haematology
Description: Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Haematology
Description: Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical examination
Description: Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical examination
Description: Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vital signs
Description: Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vital signs
Description: Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urine pregnancy test
Description: For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Urine pregnancy test
Description: For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Completion of patient diary card
Description: Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
Study NCT00432913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Completion of patient diary card
Description: Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
Study NCT01576666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study NCT01576666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT03387891 — intervention group
Intervention type: DEVICE
Intervention: Cortrium C3 device
Description: Paired measurements of data from C3 device with golden standard methods or equipment
Study NCT00943254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Tech Education
Description: Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
Study NCT00943254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Tech Education
Description: Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
Study NCT05466981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Counseling
Description: The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
Study NCT01350713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidone iodine
Description: one local application of 10% povidone iodine ointment
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT01350713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone iodine
Description: one local application of 10% povidone iodine ointment
Study NCT02490943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress Before Injection
Description: Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
Study NCT02490943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Compress After Injection
Description: Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
Study NCT03745638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Study NCT01186003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
Study NCT03600493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
Study NCT03600493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
Study NCT03420313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone sublingual tablets
Description: 24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Study NCT03867110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80 mg
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT00742924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT03745638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study NCT02795299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gerilimzumab
Description: Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
Study NCT02795299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.
Study NCT02795299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.